Research: 2010–2014
🐀 = animal study 🧬 = genetics focus 📚 = systematic review / meta-analysis
All periods: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999
Jump to: 2013 | 2012 | 2011 | 2010
2014
Bauman TM, Sehgal PD, Johnson KA, et al. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate. 2014;74(9):923–932. doi:10.1002/pros.22810 | PubMed
Bissegger S, Martyniuk CJ, Langlois VS. Transcriptomic profiling in Silurana tropicalis testes exposed to finasteride. Gen Comp Endocrinol. 2014;203:137–145. doi:10.1016/j.ygcen.2014.01.018 | PubMed
Casabé A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727-733. doi:10.1016/j.juro.2013.09.059 | PubMed
🧬 Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers. 2014;29(4):e310–e316. doi:10.5301/jbm.5000095 | PubMed
Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014:329456. doi:10.1155/2014/329456 | PubMed
Di Loreto C, La Marra F, Mazzon G, et al. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. PLoS One. 2014;9(6):e100237. doi:10.1371/journal.pone.0100237 | PubMed | PMC full text
Duijnhoven RG, Straus SM, Souverein PC, et al. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control. 2014;25(11):1577-1582. doi:10.1007/s10552-014-0455-6 | PubMed
Famenini S, Gharavi NM, Beynet DP. Finasteride associated melasma in a Caucasian male. J Drugs Dermatol. 2014;13(4):484-486. PubMed | Journal site
Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828-1834. doi:10.1016/j.juro.2013.12.014 | PubMed
📚 Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554-1566. doi:10.1111/jsm.12525 | PubMed
Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498.e3. doi:10.1016/j.jaad.2013.10.049 | PubMed
📚 Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014;25(2):156-161. doi:10.3109/09546634.2013.813011 | PubMed
Hogan C, Le Noury J, Healy D, Mangin D. One hundred and twenty cases of enduring sexual dysfunction following treatment. Int J Risk Saf Med. 2014;26(2):109-116. doi:10.3233/JRS-140617 | PubMed
Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol. 2014;150(12):1361-1363. doi:10.1001/jamadermatol.2014.1830 | PubMed
Irwig MS. Persistent sexual and nonsexual adverse effects of finasteride in younger men. Sex Med Rev. 2014;2(1):24-35. doi:10.1002/smrj.19 | PubMed
Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351-1357. doi:10.1111/ijd.12060 | PubMed
🐀 Modol L, Casas C, Navarro X, et al. Neonatal finasteride administration alters hippocampal α4 and δ GABAAR subunits expression and behavioural responses to progesterone in adult rats. Int J Neuropsychopharmacol. 2014;17(2):259-273. doi:10.1017/S1461145713000989 | PubMed
Ryu HJ, Kwon DY. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia. Dermatol Surg. 2014;40(5):595-597. doi:10.1111/dsu.12458 | PubMed
Singh MK, Avram M. Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring? J Clin Aesthet Dermatol. 2014;7(12):51-55. PubMed
🐀 Singh S, Moksha L, Sharma N, Titiyal JS, Biswas NR, Velpandian T. Development and evaluation of animal models for sex steroid deficient dry eye. J Pharmacol Toxicol Methods. 2014;70(1):29–34. doi:10.1016/j.vascn.2014.03.004 | PubMed
Traish AM, Guay AT, Zitzmann M. 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis. Horm Mol Biol Clin Investig. 2014;20(3):73-80. doi:10.1515/hmbci-2014-0025 | PubMed
Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367-379. doi:10.4111/kju.2014.55.6.367 | PubMed
Tsuji Y, Nakayama T, Bono K, Kitamura M, Imafuku I. [Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan]. Rinsho Shinkeigaku. 2014;54(5):423-8. Japanese. doi:10.5692/clinicalneurol.54.423 | PubMed
Varothai, S, Bergfeld, WF. Androgenetic Alopecia: An Evidence-Based Treatment Update. Am J Clin Dermatol. 2014;15:217–230. doi:10.1007/s40257-014-0077-5 | PubMed
Yim E, Nole KL, Tosti A. 5α-reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):493-498. doi:10.1097/MED.0000000000000112 | PubMed
2013
Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. J Urol. 2013;190(5):1811-1814. doi:10.1016/j.juro.2013.04.132 | PubMed
Collier R. Propecia lawsuits: the lasting effects of delayed drug warnings. CMAJ. 2013;185(10):E455-E456. doi:10.1503/cmaj.109-4488 | PubMed
Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12(1):81-90. doi:10.1517/14740338.2013.742885 | PubMed
Irwig MS. Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report. Alcohol Clin Exp Res. 2013;37(11):1823-1826. doi:10.1111/acer.12177 | PubMed
Lee JW, Lee HJ. Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma. Cutan Ocul Toxicol. 2013. doi:10.3109/15569527.2012.733788 | PubMed
Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, Singh S. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor – dutasteride. J Clin Pharm Ther. 2013 Oct;38(5):405-15. doi:10.1111/jcpt.12080 | PubMed
Melcangi RC, Caruso D, Abbiati F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10(10):2598-2603. doi:10.1111/jsm.12269 | PubMed
Millsop JW, Heller MM, Eliason MJ, Murase JE. Dermatological medication effects on male fertility. Dermatol Ther. 2013;26(4):337–346. doi:10.1111/dth.12069 | PubMed
🐀 Mòdol L, Darbra S, Vallèe M, Pallarès M. Alteration of neonatal allopregnanolone levels affects exploration, anxiety, aversive learning and adult behavioural response to intrahippocampal neurosteroids. Behav Brain Res. 2013;241:96-104. doi:10.1016/j.bbr.2012.11.043 | PubMed
Motofei IG, Rowland DL, Georgescu SR, et al. A pilot study on the sexual side effects of finasteride as related to hand preference for men undergoing treatment of male pattern baldness. BJU Int. 2013;111(4 Pt B):E221-6. doi:10.1111/j.1464-410X.2012.11580.x | PubMed
Nusbaum AG, Rose PT, Nusbaum BP. Nonsurgical therapy for hair loss. Facial Plast Surg Clin North Am. 2013 Aug;21(3):335-42. doi:10.1016/j.fsc.2013.04.003 | PubMed
Opoku-Acheampong AB, Unis D, Henningson JN, Beck AP, Lindshield BL. Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice. PLoS One. 2013 Oct 18;8(10):e77738. doi:10.1371/journal.pone.0077738 | PubMed | PMC full text
Şalvarci A, Istanbulluoğlu O. Secondary infertility due to use of low-dose finasteride. Int Urol Nephrol. 2013;45(1):83-85. doi:10.1007/s11255-012-0315-9 | PubMed
Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100(6):1542–1546. doi:10.1016/j.fertnstert.2013.07.2000 | PubMed
[Comment] Hotaling JM. Finasteride and male infertility: a case for prospective collaborative research databases? Fertil Steril. 2013 Dec;100(6):1528-9. doi:10.1016/j.fertnstert.2013.08.023 | PubMed
Stanczyk FZ, Azen CG, Pike MC. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:10–16. doi:10.1016/j.jsbmb.2013.02.015 | PubMed
[Comment] Traish AM, Morgentaler A. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:462. doi:10.1016/j.jsbmb.2013.06.013 | PubMed
📚 Trost L, Saitz TR, Hellstrom WJ. Side effects of 5-alpha reductase inhibitors: a comprehensive review. Sex Med Rev. 2013;1(1):24-41. doi:10.1002/smrj.3 | PubMed
🐀 Zhang MG, Wang XJ, Shen ZJ, Gao PJ. Long-term oral administration of 5α-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats. Urology. 2013;82(3):743.e9–743.e7.43E15. doi:10.1016/j.urology.2013.02.045 | PubMed
🐀 Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs. Chin Med J (Engl). 2013;126(4):711–715. doi:10.3760/cma.j.issn.0366-6999.20122496 | PubMed
2012
Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012:530121. doi:10.1155/2012/530121 | PubMed
Becker CD, Stichtenoth DO, Wichmann MG, Schaefer C, Szinicz L. Blood donors on medication – an approach to minimize drug burden for recipients of blood products and to limit deferral of donors. Transfus Med Hemother. 2009;36(2):107-113. doi:10.1159/000203355 | PubMed | PMC full text
Berthold D, Lhermitte B, Uffer M, Doerfler A. Finasteride-related Leydig cell tumour: report of a case and literature review. Andrologia. 2012;44 Suppl 1:836-837. doi:10.1111/j.1439-0272.2011.01214.x | PubMed
Corona G, Rastrelli G, Maseroli E, et al. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. J Endocrinol Invest. 2012;35(10):915-920. doi:10.3275/8510 | PubMed
Delfino M, Motola D, Mazzucchelli PP, Barotto M, Benini A, Campi A. Finastride e carcinoma mammario nell’uomo. Prima segnalazione di sospetta ADR in Italia [Finasteride and male breast cancer. First report of suspected ADR in Italy]. GIFAC. 2012. Italian. doi:10.1721/1109.12204
Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24;379(9821):1103-11. doi:10.1016/S0140-6736(11)61619-X | PubMed
🐀 Garcia PV, Barbieri MF, Perobelli JE, et al. Morphometric-stereological and functional epididymal alterations and a decrease in fertility in rats treated with finasteride and after a 30-day post-treatment recovery period. Fertil Steril. 2012 Jun;97(6):1444-51. doi:10.1016/j.fertnstert.2012.03.025 | PubMed
Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220-1223. doi:10.4088/JCP.12m07887 | PubMed
Irwig MS. Persistent sexual side effects of finasteride: Could they be permanent? J Sex Med. 2012 Nov;9(11):2927-32. doi:10.1111/j.1743-6109.2012.02846.x | PubMed
[Comment] Canguven O, Talib RA. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2013;10(5):1441. doi:10.1111/jsm.12089 | Journal site
🐀 Jarvi K. Hairless or fertile? Finasteride leads to epididymal changes and infertility in rats. Fertil Steril. 2012 Jun;97(6):1298. doi:10.1016/j.fertnstert.2012.04.016 | PubMed
Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66(11):1052-1055. doi:10.1111/j.1742-1241.2012.03010.x | PubMed
Kuehn BM. Prostate, baldness drugs linked to sexual dysfunction. JAMA. 2012;307(18):1903. doi:10.1001/jama.2012.4488 | PubMed
La Marra F, Di Loreto C, Mazzon G, et al. Preliminary evidence of a peculiar hormonal profile in men with adverse effects after use of finasteride against androgenetic alopecia. Am J Pathol. 2012;181:S8. doi:10.1016/S0002-9440(12)00566-4
Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J. 2012;3(1):62-65. doi:10.4103/2229-5178.93496
🐀 Oztekin CV, Gur S, Abdulkadir NA, Lokman U, Akdemir AÖ, Cetinkaya M, Hellstrom WJ. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med. 2012;9(7):1773–1781. doi:10.1111/j.1743-6109.2012.02759.x | PubMed
Ricci G, Martinelli M, Luppi S, et al. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol. 2012;11(12):1511–1513. doi:10.1111/dth.12069 | PubMed
Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012 Jan;39(1):27-32. doi:10.1111/j.1346-8138.2011.01378.x | PubMed
Shin SY, Shin YH, Lee SW, Shin JY, Kim CH. Blood donors on teratogenic drugs and donor deferral periods in a clinical situation. Vox Sang. 2012 May;102(4):362-4. doi:10.1111/j.1423-0410.2011.01566.x | PubMed
Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract. 2012;18(6):965–975. doi:10.4158/EP12108.RA | PubMed
Tresch S, Cozzio A, Kamarashev J, et al. T cell-mediated acute localized exanthematous pustulosis caused by finasteride. J Allergy Clin Immunol. 2012 Feb;129(2):589-94. doi:10.1016/j.jaci.2011.07.033 | PubMed
Wambier CG, Pereira CS, Prado Júnior Bde P, Foss NT. Brazilian blood donation eligibility criteria for dermatologic patients. An Bras Dermatol. 2012 Jul-Aug;87(4):590-5. doi:10.1590/s0365-05962012000400012 | PubMed
Zhang MG, Wu W, Zhang CM, et al. Effects of oral finasteride on erectile function in a rat model. J Sex Med. 2012 May;9(5):1328-36. doi:10.1111/j.1743-6109.2012.02661.x | PubMed
2011
Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol. 2011 Sep;52(9):632-6. doi:10.4111/kju.2011.52.9.632 | PubMed
Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95(5):. doi:10.1016/j.fertnstert.2010.12.001 | PubMed
Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011 Oct;60(4):809-25. doi:10.1016/j.eururo.2011.06.037 | PubMed
Goldstein I. An old problem with a new cause-5 alpha reductase inhibitors and persistent sexual dysfunction. J Sex Med. 2011;8(7):1829–1831. doi:10.1111/j.1743-6109.2011.02368.x | PubMed
[Comment] Uribe JF. Persistent sexual dysfunction and 5 alpha reductase inhibitors. J Sex Med. 2012;9(9):2475. doi:10.1111/j.1743-6109.2012.02676.x | PubMed
Gude D. Finasteride and male fertility. J Hum Reprod Sci. 2011 May;4(2):101-2. doi:10.4103/0974-1208.86093 | PubMed | PMC full text
Hwang TIS. Will medical management of benign prostatic hyperplasia result in better or worse sexual function in men? Urological Science. 2011;22(1):14-18. doi:10.1016/S1879-5226(11)60003-1
Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-1753. doi:10.1111/j.1743-6109.2011.02255.x | PubMed
🐀 Kolasa A, Marchlewicz M, Wenda-Różewicka L, Wiszniewska B. DHT deficiency perturbs the integrity of the rat seminiferous epithelium by disrupting tight and adherens junctions. Folia Histochem Cytobiol. 2011;49(1):62-71. doi:10.5603/fhc.2011.0010 | PubMed
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011 Aug;108(3):388-94. doi:10.1111/j.1464-410X.2011.10195.x | PubMed
🐀 Paris JJ, Brunton PJ, Russell JA, Walf AA, Frye CA. Inhibition of 5α-reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progestogen milieu of juvenile rat offspring. J Neuroendocrinol. 2011;23(11):1079-1090. doi:10.1111/j.1365-2826.2011.02219.x | PubMed | PMC full text
🐀 Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8(11):3066–3074. doi:10.1111/j.1743-6109.2011.02425.x | PubMed
Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455–461. doi:10.1111/j.1529-8019.2011.01441.x | PubMed
Santo Domingo D, Stevenson ML, Auerbach J, Lerman J. Finasteride-induced pseudoporphyria. Arch Dermatol. 2011;147(6):747‐748. doi:10.1001/archdermatol.2011.144 | PubMed
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872-884. doi:10.1111/j.1743-6109.2010.02157.x | PubMed
Tu HY, Zini A. Finasteride-induced secondary infertility associated with sperm DNA damage. Fertil Steril. 2011;95(6):2125.e13–2125.e14. doi:10.1016/j.fertnstert.2010.12.061 | PubMed
Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011 Jul;37(7):1351-4. doi:10.1016/j.jcrs.2011.04.013 | PubMed
2010
🐀 Darbra S, Pallarès M. Alterations in neonatal neurosteroids affect exploration during adolescence and prepulse inhibition in adulthood. Psychoneuroendocrinology. 2010;35(4):525-535. doi:10.1016/j.psyneuen.2009.08.020 | PubMed
Dušková M, Hill M, Stárka L. The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids. Horm Mol Biol Clin Investig. 2010 Jan 1;1(2):95-102. doi:10.1515/HMBCI.2010.010 | PubMed
Laborde E, Brannigan RE. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 2010 Mar-Apr;31(2):e1-2. doi:10.2164/jandrol.109.009381 | PubMed | Wiley Free Access
Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?. Dermatol Ther. 2010;23(5):544-546. doi:10.1111/j.1529-8019.2010.01358.x | PubMed
📚 Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146(10):1141-1150. doi:10.1001/archdermatol.2010.256 | PubMed
Moreno-Fernandez A, Mira Laguarda JM, Ruiz-Hornillos FJ, Rubio Sotes M. Urticarial rush due to finasteride. Allergy. 2010 Mar;65(3):405-6. doi:10.1111/j.1398-9995.2009.02165.x | PubMed
Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced Gynecomastia: Case report and Review of the Literature. Int J Trichology. 2009;1(1):27–29. doi:10.4103/0974-7753.51930 | PubMed
Römer B, Gass P. Finasteride-induced depression: new insights into possible pathomechanisms [published correction appears in J Cosmet Dermatol. 2011 Mar;10(1):85]. J Cosmet Dermatol. 2010;9(4):331-332. doi:10.1111/j.1473-2165.2010.00533.x | PubMed
🐀 Römer B, Pfeiffer N, Lewicka S, et al. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry. 2010;43(5):174-178. doi:10.1055/s-0030-1249095 | PubMed
📚 Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010 Oct 6;2010(10):CD006015. doi:10.1002/14651858.CD006015.pub3 | PubMed | PMC full text
Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011;37(7):1351‐1354. doi:10.1016/j.jcrs.2011.04.013 | PubMed
Bibliographies: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999